GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Bioethics BOTH · USD

N/A · US listing · 🇺🇸 United States

Compare

0.01

—

Close of 30 Oct 2026, in USD

About Bioethics

Its shares trade under the ticker BOTH. It has been listed since 20 April 1998.

Bioethics Ltd. is a shell company. The company is headquartered in Ogden, Utah. The firm is formed for the purpose of entering a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The firm has not selected any specific business combination target and has not, nor has anyone on its behalf, initiated any substantive discussions, directly or indirectly, with any business combination target. The firm has not commenced any operations nor generated any revenue.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
N/A
Industry
N/A
Listed since
20 Apr 1998

Leadership

Pay as last reported

  • Mr. Mark ScharmannPresident, Chief Executive Officer, Director, since 2015
  • Mr. Elliott TaylorDirector

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • No operational costs due to zero full-time employees.
  • No debt or financial obligations as a shell company.
  • No need for immediate revenue generation.

Weaknesses

  • No employees to execute business plans or operations.
  • No revenue or financial performance to attract investors.
  • No established business model or target for merger.

Opportunities

  • Potential merger with a profitable company in the Health Care sector.
  • Opportunity to acquire assets in the Information Technology industry.
  • Possible partnership with a company in the Materials sector.

Threats

  • Risk of failing to find a suitable merger target within the timeframe.
  • Potential regulatory hurdles in the Financials sector for mergers.
  • Threat of shareholder lawsuits if no merger occurs within the specified period.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.